Following the publication of the Commission of Investigation’s Final Report, I corresponded with Glaxo Smith Kline (GSK), the lead entity in many trials. I also had a meeting with representatives of the company. In this engagement I conveyed my view that all relevant parties have a moral and ethical obligation to take appropriate action in response to the Report. The timeline of these interactions is outlined below.
12/3/2021
|
Letter to GSK CEO Re MBH Commission of Investigation Report
|
23/3/2021
|
Letter From GSK Ireland GM Re Correspondence
|
25/3/2021
|
Email from GSK Ireland Re Correspondence
|
25/3/2021
|
Internal Email Sharing GSK Correspondence
|
28/4/2021
|
Meeting between Minister and GSK
|
30/4/2021
|
Email Re Meeting Between GSK and Minister
|
31/5/2021
|
Email Thread With Comments on Meeting
|
31/5/2021
|
Letter from GSK Ireland
|
01/9/2021
|
Email Re GSK Information Service
|
01/9/2021
|
Letter Re GSK Information Service
|
The details of this correspondence were released by my Department through FOI in November 2021.
In my communications with GSK I urged them to consider the failures laid bare in the Commission’s report and respond appropriately, given their corporate responsibilities. In correspondence to me, and published by GSK, the company outlined their engagement with the Commission of Investigation and noted the conclusions reached by the Commission. They confirmed that they do not propose to pay reparations in response to the issues raised in the Commission's report.
Ultimately, it is a matter for GSK to decide what action they take, or remedy they offer, having considered the Commission’s findings.
I am aware that GSK have since publicised arrangements for persons wishing to access personal information which may be contained within their corporate archives.